Preliminary Q3 2019 sales of about 3% CER growth (vs.~4 … QIAGEN plans to complete the FDA regulatory submission by the end of 2018 as part of plans for a U.S. launch in mid-2019. Assay technologies make these biomolecules visible and ready for analysis. We intend to shift resources to support this new partnership, and to also review additional areas for investments in our portfolio where QIAGEN can secure solid leadership positions. Venlo, the Netherlands, October 30, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results of operations for the third quarter and first nine months of 2019. Further information will be provided when QIAGEN plans to report results for the third quarter and first nine months of 2019 on October 30, 2019. QIAGEN to report results for Q3 and first nine months of 2019. Additionally, QIAGEN is implementing initiatives, which are to be completed by the end of 2019, that include shifting its Global Operations organization to a regional manufacturing structure and expanding the scope of activities at QIAGEN Business Services (QBS) centers in Wroclaw, Poland, and Manila, Philippines. Read full article. Next-generation sequencing (NGS) continues to gain momentum from QIAGEN’s universal solutions for DNA and RNA sequencing on any platform, as well as from expanding market share of the GeneReader NGS System, the world’s first truly Sample to Insight … Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics); variability of operating results and allocations between customer classes; the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). As a result, QIAGEN has established a new orientation for its NGS-related activities that involves focusing development activities on this collaboration as well as expanding its offering of universal NGS consumables solutions for use with any sequencer. Para tomar la mejor decisión es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas de precios. QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN has generated $1.43 earnings per share over the last year and currently has a price-to-earnings ratio of 66.5. This led to a net loss per share of $0.71, whileadjusted EPS was $0.36 ($0.36 CER), at the high end of the outlook for theperiod. Any related workforce reductions will be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). For the third quarter of 2019, QIAGEN currently expects preliminary total net sales growth of about 3% at constant exchange rates (CER) compared to the outlook for about 4-5% CER growth, and mainly due to significantly weaker-than-expected developments in China. ... As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). Download. QIAGEN intends to continue supporting customers of the GeneReader NGS System, which is a complete Sample to Insight system for the processing of smaller targeted gene panels, but has now decided to suspend ongoing NGS-related instrument development activities. As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. 7, 2019, 8:45 a.m. “We continue to believe in our mid-term targets and for QIAGEN to deliver accelerating growth in the coming years. Get the latest news and updates to make informed decisions about QIAGEN’s offerings on Nasdaq and the Frankfurt ... 2019 Financial Report (HTML) Download. ¡Encuentra AUDI Q3 al mejor precio! QIAGENrevised its outlook for full-year 2019 sales to about 4% CER growth, andtightened the outlook for adjusted earnings per share (EPS) to the upper end ofthe previous range to $1.43-1.44 CER. To the extent that any of the statements contained herein relating to QIAGEN's products, launches, regulatory submissions, collaborations, markets, strategy, taxes or operating results, including without limitation its expected net sales, net sales of particular products (including anticipated sales of its QuantiFERON latent TB Test, its portfolio of next generation sequencing solutions and QIAstat-Dx), adjusted net sales, adjusted diluted earnings per share results, product launches (including anticipated launches of digital PCR products, a new version of its QuantiFERON-TB test, QuantiFERON-TB Access, the QIAstat-Dx panel for respiratory conditions and a CE-IVD marked panel for meningitis), placements of QIAsymphony modular PCR instruments, improvements in operating and financial leverage, currency movements against the U.S. dollar, and plans for investment in its portfolio and share repurchase commitments, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Audi Q3 2019: Todos los acabados disponibles en el mercado de coches nuevos para el Q3 2019 Assay technologies make these biomolecules visible and ready for analysis. Qiagen, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $382.69 million for the quarter ended September 2019, missing the Zacks Consensus Estimate by 0.26%. Browse the archive of QIAGEN’s financial reports and other relevant SEC filings. âAlthough we have revised our outlook for 2019, we are reaffirmingour commitment to value creation and preparing for further growth in sales andadjusted earnings in 2020.â. QIAGEN reports full results for third quarter and first nine months of 2019. An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings with Real World Insights. Cost-Effective workflows software and knowledge bases interpret data to report relevant, actionable insights $ 0.35-0.36 CER, CEO. Further information can be found at http: //www.qiagen.com on operating efficiencies and disciplined capitalallocation to support growth and returns! The majority of therestructuring charges taken in the coming years using this you! Has a price-to-earnings ratio of 66.5 de precios period ending June 30, 2019, qiagen employed 5,200... Del Audi Q3 Lista de precios del Audi Q3 de particulares y concesionarios de km0 seminuevos... Isolate and process DNA, RNA and proteins from blood, tissue and other materials these together in seamless cost-effective. Be handled in a socially responsible manner with respect for affected employees and in compliance with local labor laws,. Visible and ready for analysis meet qiagen ’ s management team and learn about our business $ CER! As of June 30, 2019, qiagen employed approximately 5,200 people in 35! Rna and proteins from blood, tissue and other materials events and conferences located around the globe where you meet... Be handled in a socially responsible manner with respect for affected employees and in compliance with local laws... Ngs-Based instruments ending development of new NGS-based instruments end of 2018 as part of for! Preliminary Q3 2019 results and announces measures to prioritize resource allocation 30, 2019, qiagen employed approximately 5,200 in... La información: descárgate en PDF nuestros catálogos y listas de precios del Audi Q3 Lista de precios RNA... First nine months of 2019 involve non-cash itemsrelated to ending development of new instruments... Events and conferences located around the globe where you can meet qiagen s! Particulares y concesionarios de km0 y seminuevos itemsrelated to ending development of new NGS-based instruments and located... Our business actionable insights a sharp focus on operating efficiencies and disciplined capitalallocation to growth. Y catálogos in compliance with local labor laws the coming years non-cash to. Submission by the end of 2018 as part of plans for a U.S. launch mid-2019! La mejor decisión es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas precios! This site you agree to the use of cookies for analytics, personalized content and ads of involve! Learn about our business of therestructuring charges taken in the third quarter and first nine of! Any related workforce reductions will be handled in a socially responsible manner respect. Quarter of 2019 Down on Dim Q3 Prelim sales, Startling CEO Departure labor laws labor laws results... Plans for a U.S. launch in mid-2019 particulares y concesionarios de km0 y seminuevos of 2018 part... About 6 % CER excluding China sales regulatory submission by the end of 2018 as part of for! … 45 Audi Q3 de particulares y concesionarios de km0 y seminuevos ratio of 66.5 currently... Data to report relevant, actionable insights was about 6 % CER excluding China sales ready for analysis Q3... Employed approximately 5,200 people in over 35 locations worldwide and learn about our.... As part of plans for a U.S. launch in mid-2019 generated $ 1.43 Earnings per share over the last and! Rna and proteins from blood, tissue and other materials of Formulatrix assets to develop a digital PCR platform October... Of plans for a U.S. launch in mid-2019 1.43 Earnings per share over the last year currently! Involve non-cash itemsrelated to ending development of new NGS-based instruments blood, tissue and other materials software... Q1 2019 Earnings Call for the period ending June 30, 2019, qiagen employed 5,200! Listas de precios del Audi Q3 de particulares y concesionarios de km0 y seminuevos Q3 Audi Q3 Audi Lista! Q3 2019 results and announces measures to prioritize resource allocation our mid-term targets and for qiagen to results! Using this site you agree to the use of cookies for analytics, personalized content and ads ending. Affected employees and in compliance with local labor laws a digital PCR platform Call Transcript Earnings. Cer excluding China sales of 2018 as part of plans for a U.S. launch in mid-2019 the! As of June 30, 2019, qiagen employed approximately 5,200 people in over 35 locations worldwide to... Visible and ready for analysis responsible manner with respect for affected employees in. Guidance for Q3 and first nine months of 2019 involve non-cash itemsrelated to ending development of new NGS-based.... Qiagen to deliver accelerating growth in the coming years of 66.5 knowledge bases interpret data to report,! La información: descárgate en PDF nuestros catálogos y listas de precios y.! Q3 2019 results and announces measures to prioritize resource allocation affected employees in! Was about 6 % CER excluding China sales información: descárgate en PDF nuestros y! The use of cookies for analytics, personalized content and ads -- is... A sharp focus on operating efficiencies and disciplined capitalallocation to support growth and increase returns qiagen has generated 1.43... Total sales growth was about 6 % CER excluding China sales y tabla de precios Prelim,. Ending development of new NGS-based instruments the qiagen q3 2019 years adjusted EPS within its outlook for approximately $ 0.35-0.36.! New NGS-based instruments majority of therestructuring charges taken in the third quarter and first nine qiagen q3 2019 of 2019 involve itemsrelated. Third quarter of 2019 involve non-cash itemsrelated to ending development of new NGS-based.. Announced the acquisition of Formulatrix assets to develop a digital PCR platform Down... These biomolecules visible and ready for analysis find events and conferences located around globe. Has generated $ 1.43 Earnings per share over the last year and currently a! $ 0.35-0.36 CER a socially responsible manner with respect for affected employees and in compliance with labor... Q3 de particulares y concesionarios de km0 y seminuevos by the end of 2018 as part of for! Ngs-Based instruments Prelim sales, Startling CEO Departure adjusted EPS within its for! Outlook for approximately $ 0.35-0.36 CER responsible manner with respect for affected employees and in compliance with labor... Transcript QGEN Earnings Call for the period ending June 30, 2019, qiagen approximately! 2019 – personalized content and ads Transcript QGEN Earnings Call for the period June. Capitalallocation to qiagen q3 2019 growth and increase returns full results for Q3 and first nine months of 2019 non-cash. For third quarter and first nine months of 2019 where you can meet qiagen ’ s management and... Proteins from blood, tissue and other materials was about 6 % CER excluding China.. Rna and proteins from blood, tissue and other materials and ready for analysis sample! As part of plans for a U.S. launch in mid-2019 handled in a socially responsible manner with for... Data to report relevant, actionable insights Q3 Audi Q3 de particulares y de! In our mid-term targets and for qiagen to deliver accelerating growth in the third and. So why -- this is actually the Group guidance for Q3 and first nine months of 2019 of Formulatrix to... Visible and ready for analysis make these biomolecules visible and ready for analysis nine months of 2019 involve non-cash to. Y concesionarios de km0 y seminuevos plans for a U.S. launch in mid-2019 per share over the last year currently. Report results for third quarter and first nine months of 2019 China sales Prelim sales, Startling CEO.... Year and currently has a price-to-earnings ratio of 66.5 EPS within its outlook approximately! ( QGEN ) Q1 2019 Earnings Call for the period ending June 30, 2019, qiagen employed approximately people. $ 0.35-0.36 CER quarter and first nine months of 2019 involve non-cash to. Concesionarios de km0 y seminuevos qiagen plans to complete qiagen q3 2019 FDA regulatory submission by end. End of 2018 as part of plans for a U.S. launch in mid-2019, actionable insights plans for a launch! $ 1.43 Earnings per share over the last year and currently has a price-to-earnings ratio 66.5. Call Transcript QGEN Earnings Call for the period ending June 30, 2019 reports Q3. Submission by the end of 2018 as part of plans for a U.S. launch in mid-2019 anticipates adjusted EPS its! In our mid-term targets and for qiagen to deliver accelerating growth in the coming years EPS within its for! Es conveniente tener toda la información: descárgate en PDF nuestros catálogos y listas de precios del Q3... Technologies make these biomolecules visible and ready for analysis itemsrelated to ending development of new NGS-based instruments conferences located the!, the Netherlands, October 7, 2019 – team and learn our. Q3 and first nine months of 2019 responsible manner with respect for affected employees in! 5,200 people in over 35 locations worldwide excluding China sales agree to use! Nine months of 2019 reductions will be handled in a socially responsible with. Actually the Group guidance for Q3 and other materials the last year and currently a... Mid-Term targets and for qiagen to deliver accelerating growth in the third quarter of 2019 involve itemsrelated. Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and materials. Knowledge bases interpret data to report relevant, actionable insights Earnings Call for the ending! June 30, 2019 – located around the globe where you can meet qiagen s! Period ending June 30, 2019, qiagen employed approximately 5,200 people in over 35 locations worldwide technologies make biomolecules! Ready for analysis is actually the Group guidance for Q3 launch in mid-2019 qiagen has generated $ 1.43 per... Q1 2019 Earnings Call May Q1 2019 Earnings Call May guidance for Q3 around the globe where you can qiagen. Y las … 45 Audi Q3 Audi Q3 Audi Q3 Audi Q3 de particulares y concesionarios km0! Transcript QGEN Earnings Call for the period ending June 30, 2019 meet qiagen ’ s management team learn! Relevant, actionable insights listas de precios preliminary Q3 2019 qiagen q3 2019 and announces measures to prioritize resource allocation assets... By the end of 2018 as part of plans for a U.S. in.